Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 187-196

  Bruno, René ^a   Hille, Darcy ^a   Riva, Alessandro ^a   Vivier, Nicole ^a   Ten Bokkel Huinnink, Wim W ^a   Van Oosterom, Allan T ^a   Kaye, Stan B ^a   Verweij, Jaap ^a   Fossella, Frank V ^a   Valero, Vicente ^a   Rigas, James R ^a   Seidman, Andrew D ^a   Chevallier, Bernard ^a   Fumoleau, Pierre ^a   Burris, Howard A ^a   Ravdin, Peter M ^a   Sheiner, Lewis B ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLUID RETENTION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031982748     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.187     Document Type: Article

References (54)

1. Rowland M, Aarons L (eds): New Strategies in Drug Development and Clinical Evaluation: The Population Approach. Brussels, Belgium, Commission of European Communities, 1992
2. Peck CC, Barr WH, Bennet LZ, et al: Conference report: Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 51:465-473, 1992
3. Vozeh S, Steimer JL, Rowland M, et al: The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30:81-93, 1996
4. Sheiner LB, Ludden TM: Population pharmacokinetics/dynamics. Ann Rev Pharmacol Toxicol 32:185-190, 1992
5. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
6. Pronk LC, Stoter G, Verweij J: Docetaxel (Taxotere): Single agent activity, development of combination treatments and reducing sideeffects. Cancer Treat Rev 21:463-478, 1995
7. Bruno R, Vivier N, Vergniol JC, et al: A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokinet Biopharm 24:153-172, 1996
8. Dieras V, Fumoleau P, Chevallier B, et al: Second EORTC-Clinical Screening Group phase II trial of Taxotere (docetaxel) as first line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 13:78, 1994 (abstr 115)
9. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532, 1994
10. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
11. Guastalla JP, Bonneterre J, Fumoleau P, et al: A phase II trial of docetaxel in patients with anthracycline resistant metastatic breast cancer. Eur J Cancer 31A:S75-S76, 1995 (suppl 5, abstr 348)
12. Ravdin PM, Burris III HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
13. Valero V, Holmes F, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
14. Fumoleau P, Chevallier B, Kerbrat P, et al: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996
15. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
16. Burris H, Eckardt J, Fields S, et al: Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 12:335, 1993 (abstr 1116)
17. Cerny T, Kaplan S, Pavlidis N. et al: Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 70:384-387, 1994
18. Fossella FV, Lee JS, Murphy WK et al: Phase II trial of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12:1238-1244, 1994
19. Francis PA, Rigas JR, Kris MG et al: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12:1232-1237, 1994
20. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
21. Miller VA, Rigas JR, Francis PA, et al: Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
22. Kavanagh GH, Kudelka AP, Gonzalez de Leon C, et al: Phase II trial of docetaxel in patients with epitelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837-842, 1996
23. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533-537, 1994
24. Aamdal S, Wolff I, Kaplan S, et al: Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1061-1064, 1994
25. Bruntsch U, Heinrich B, Kaye SB, et al: Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1064-1067, 1994
26. Son L, Pazdur R, Lassere Y, et al: Phase II trial of docetaxel (Taxotere) in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 35:230, 1994 (abstr 1372)
27. Clark T, Kemeny N, Conti JA, et al: Phase II trial of docetaxel (Taxotere, RP 56976) in previously untreated patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 13:212, 1994 (abstr 635)
28. Sternberg CN, Ten Bokkel Huinink WW, Smyth JF, et al: Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group study. Br J Cancer 70:376-379, 1994
29. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70:380-383, 1994
30. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A: 1058-1060, 1994
31. Van Hoesel QGCM, Verweij J, Catimel G, et al: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5:539-542, 1994
32. Sheiner LB, Benet LZ: Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 38:481-487, 1985
33. Hashimoto Y, Sheiner LB: Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 19:333-353, 1991
34. Launay-Iliadis MC, Bruno R, Cosson V, et al: Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 37:47-54, 1995
35. D'Argenio DZ: Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739-756, 1981
36. Iliadis A, Brown AC, Huggins ML: APIS: A software for model identification, simulation and dosage regimen calculations in clinical pharmacokinetics. Comput Methods Programs Biomed 38:227-239, 1992
37. Vergniol JC, Bruno R, Montay G, et al: Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278, 1992
38. Beal SL, Boeckman AJ, Sheiner LB: NONMEM. User's Guide Part I to VI. San Francisco, CA, University of California at San Francisco, 1988-1992
39. Van Warmerdam LJC, ten Bokkel Huinink WW, Maes RAA, et al: Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120:427-433, 1994
40. Bruno R, Iliadis M-C, Lacarelle B, et al: Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients. J Pharmacokinet Biopharm 20:653-669, 1992
41. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
42. Urien S, Barré J, Morin C, et al: Docetaxel serum protein binding with high affinity to alphal-acid glycoprotein. Invest New Drug 14:147-151, 1996
43. Bailie P, Bruno R, Schellens JHM, et al: Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res 3:1535-1538, 1997
44. Huizing MT, Giacone G, van Warmerdam LJC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15:317-329, 1997
45. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
46. Giani L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13:180-190, 1995
47. Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599-606, 1995
48. Oulid-Aissa D, Bruno R, Lebecq A, et al: Taxotere safety in patients with impaired liver function. Proc Am Soc Clin Oncol 15:476, 1996 (abstr 1508)
49. Francis P, Bruno R, Seidman A, et al: Pharmacodynamics of Taxotere (docetaxel) in patients with liver metastases. Proc Am Soc Clin Oncol 13:138, 1994 (abstr 346)
50. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
51. Ravdin P, Valero V, Nabholtz J-M, et al: Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention. Proc Am Soc Clin Oncol 15:115, 1996 (abstr 124)
52. Kremer JMH, Wilting J, Janssen LHM: Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1-47, 1988
53. Thompson DK, Haddow JE, Smith DE, et al: Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer 51:2100-2104, 1983
54. Ganz PA, Baras M, Yeung Ma P, et al: Monitoring the therapy of lung cancer with α-1-acid glycoprotein. Cancer Res 44:5415-5421, 1984